Navigation Links
Microbix And Hunan Biopharmaceutical To Build Asia's Largest Influenza Vaccine Facility
Date:10/27/2009

least 60 percent of their populations.

Gastle added, "This facility will make China an important source of influenza vaccine in the Asia region as well as offering significant capacity for the Chinese market which is growing significantly. In five years, the China market is expected to demand up to 500 million influenza vaccine doses annually."

The Microbix-Hunan project brings government ownership into the global vaccine industry at a technological level not previously achieved in China. A substantial investment is being made by Hunan in transferring the land to the joint venture and building the facility through the first phase of financing. As the project progresses, Hunan has agreed to provide additional funding through debt and has guaranteed the purchase of 100 million influenza vaccine doses. On all vaccine produced at the facility, Microbix will receive royalty payments and hold exclusive marketing rights outside of China.

The quality of the vaccine manufactured at the Microbix-Hunan facility will enable it to seek approval by the U.S. Food and Drug Administration and European Medicines Agency.

Mr. He Jihua, Deputy Mayor of Changsha Municipal Government, said, "We believe we have ensured the success of this important public health initiative by choosing Microbix as our partner. They bring expertise in developing vaccine and virology technologies, manufacturing and product distribution. The established collaboration that Microbix holds with world class biomedical and public health organizations will be invaluable."

He also said that "the cooperation between the two countries, Canada and China, and the two companies, Microbix and Hunan Biopharmaceutical in building this vaccine facility will bring greater vaccine capacity and improved health to China and other regions worldwide."

Microbix CEO William J. Gastle and Changsha National Bioindustry Park Deputy Director, Mr. Chen Zhigao, signed the ag
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
6. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
7. Microbix Sales Grow 22% For Nine Months
8. Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya)
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Oklahoma City, OK (PRWEB) May 24, 2013 ... handful of casualties. And following its ravage, the mayor of ... room bill for new houses, said a report from cnn.com. ... offered the tornado victims complimentary Molderizer and Safe Shield to ... according to the report published on May 22, 2013, caused ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
(Date:5/24/2013)... Quincy Bioscience, a leading research ... calcium-binding proteins to support healthy living, is pleased ... of apoaequorin in Food and Chemical ... British Industrial Biological Research Association. , The ... adverse effects, if any, of apoaequorin, in rats ...
(Date:5/23/2013)... 2013 Die Übersetzungen wurden von ... Bei der englischen Version handelt es sich ... der Teilnehmer einer groß angelegten Asthmaumfrage halten ihren Zustand ... [*] -Definition [1] als kontrolliert gelten können ... einer von vier Denkweisen zugeordnet werden können, die alle ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... 17 Schering-Plough,Corporation (NYSE: SGP ) announced ... filed a New Drug Application with the Japanese,Ministry ... approval,for its novel selective relaxant binding agent (SRBA), ... reverse to rapidly,reverse the effects of certain muscle ...
... PXS;,Nasdaq: PXSL) today announced the Korean regulatory agency ... Aridol., "This is the first Asian approval ... Robertson. "Korea is an important base from which,to ... an estimated 2.5 million,asthma sufferers and yet only ...
... 16 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), ... year ended November 30, 2007. All dollar amounts ... At November 30, 2007, our cash and ... at November 30, 2006. The change in,our cash ...
Cached Biology Technology:Schering-Plough Announces Sugammadex New Drug Application Filed in Japan 2Schering-Plough Announces Sugammadex New Drug Application Filed in Japan 3Pharmaxis' Aridol Gains First Asian Approval 2Vasogen Announces 2007 Year-End Results 2Vasogen Announces 2007 Year-End Results 3Vasogen Announces 2007 Year-End Results 4Vasogen Announces 2007 Year-End Results 5Vasogen Announces 2007 Year-End Results 6Vasogen Announces 2007 Year-End Results 7Vasogen Announces 2007 Year-End Results 8Vasogen Announces 2007 Year-End Results 9Vasogen Announces 2007 Year-End Results 10Vasogen Announces 2007 Year-End Results 11
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... Wash. Pacific Northwest National Laboratory honored more ... commercialization of intellectual property at PNNL,s annual Intellectual ... , The Department of Energy national laboratory named ... for his work developing battery materials that can ... the electrical grid, and reduce the time it ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... designed, produced and patented a new chemical compound for the ... binds 1,000 times more effectively to the target protein in ... stroke victims. The results of biological tests have just been ... people die each year from stroke in the United States. ...
... Calif., Feb. 21, 2012  ChromaDex Corporation (OTCBB: CDXC), ... science-based solutions and ingredients to the dietary supplement, ... marketer of BluScience™ ( http://www.bluscience.com ), ... today the Board has appointed Debra A. Heim ...
... Euroscience Open Forum 2012 (ESOF 2012) was officially launched today ... place in Dublin this year from 11th to 15th July. ... be held in the heart of the Irish capital, in ... interdisciplinary, pan-European meeting, held under the auspices of Euroscience, which ...
Cached Biology News:Promising new compound for treating stroke 2Promising new compound for treating stroke 3ChromaDex® Names Debra Heim as COO 2ChromaDex® Names Debra Heim as COO 3Science Program announced for Euroscience Open Forum 2012 in Dublin 2Science Program announced for Euroscience Open Forum 2012 in Dublin 3Science Program announced for Euroscience Open Forum 2012 in Dublin 4Science Program announced for Euroscience Open Forum 2012 in Dublin 5